PRAG1: A Potential Drug Target for Various Diseases (G157285)

Target Name: PRAG1

NCBI ID: G157285

PRAG1

PRAG1: A Potential Drug Target for Various Diseases

PRAG1 (Positive Operational Analysis Group 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The gene is located on chromosome 12 and has been shown to play a role in the development and progression of these diseases.

PRAG1 is a non-coding RNA molecule that is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. The gene has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the most significant functions of PRAG1 is its role in cell adhesion. PRAG1 has been shown to be involved in the formation of tight junctions, which are critical for maintaining the integrity of the blood-brain barrier and for controlling the movement of ions and molecules into and out of cells. The loss of tight junctions has been implicated in the development of various neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

PRAG1 is also involved in the regulation of cell migration. The gene has been shown to be involved in the migration of cancer cells and other mobile cells throughout the body. The regulation of cell migration is critical for the development of tumors and the progression of cancer.

In addition to its role in cell adhesion and migration, PRAG1 is also involved in the regulation of cellular processes that are critical for the survival of cells. The gene has been shown to be involved in the regulation of apoptosis, which is the process by which cells die and are removed from the body. The regulation of apoptosis is critical for the development and progression of various diseases, including cancer.

PRAG1 is also involved in the regulation of inflammation. The gene has been shown to be involved in the regulation of inflammatory responses and the production of pro-inflammatory cytokines. The production of pro-inflammatory cytokines is critical for the development and progression of various autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

In conclusion, PRAG1 is a gene that has been shown to play a critical role in the development and progression of various diseases. The regulation of cell adhesion, migration, and apoptosis, as well as the regulation of inflammation, are all critical processes that are critical for the survival and growth of cells. The development of PRAG1 as a potential drug target or biomarker for these diseases makes it an attractive target for researchers to investigate and develop new treatments.

Protein Name: PEAK1 Related, Kinase-activating Pseudokinase 1

Functions: Catalytically inactive protein kinase that acts as a scaffold protein. Functions as an effector of the small GTPase RND2, which stimulates RhoA activity and inhibits NGF-induced neurite outgrowth (By similarity). Promotes Src family kinase (SFK) signaling by regulating the subcellular localization of CSK, a negative regulator of these kinases, leading to the regulation of cell morphology and motility by a CSK-dependent mechanism (By similarity). Acts as a critical coactivator of Notch signaling (By similarity)

The "PRAG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets